LY 2428757

Drug Profile

LY 2428757

Alternative Names: GLP-1-PEG; LY2428757; Pegylated GLP-1 analogue (LY2428757) - Eli Lilly

Latest Information Update: 21 Sep 2010

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eli Lilly
  • Developer Eli Lilly; Transition Therapeutics
  • Class Antihyperglycaemics; Glucagon-like peptides; Hormones
  • Mechanism of Action Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 20 Jul 2010 Discontinued - Phase-I for Type-2 diabetes mellitus in Puerto Rico (SC)
  • 20 Jul 2010 Discontinued - Phase-I for Type-2 diabetes mellitus in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top